Benitec (BNTC) insider buys 730,370 shares at $13.5; Form 4

Benitec Biopharma (BNTC) reported insider purchases by joint filers associated with Suvretta Capital.

Accepted by SEC EDGAR 11/10/2025 - 09:51 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Benitec Biopharma (BNTC) reported insider purchases by joint filers associated with Suvretta Capital. On 11/07/2025, the reporting persons acquired 730,370 shares of common stock at $13.5 per share and separately acquired 751,111 shares at $13.5. The holdings following these transactions were reported as 9,538,175 shares and 1,819,812 shares, respectively. The positions are listed as indirect ownership, and the filers are identified as a Director and 10% Owner. Additional explanatory notes are referenced in Exhibit 99.1.

Insights

Equity Governance Analyst

Large insider purchases by a 10% owner/director at a single price, boosting indirect holdings across two accounts.

Two related reporting persons disclosed open-market purchases of **Benitec Biopharma Inc.** common stock on 11/07/2025. At a per‑share price of $13.5, they acquired 730,370 shares in one line and 751,111 shares in another. The filing marks indirect ownership, consistent with a joint filing structure and exhibits referencing explanatory footnotes.

Post‑transaction, reported indirect beneficial ownership stands at 9,538,175 shares for one line and 1,819,812 shares for the other, with the filers identified as both **Director** and **10% Owner**. A Form 4 signals a change in insider holdings; purchases generally indicate increased exposure by insiders without asserting motive. The joint filer exhibits suggest multiple affiliated reporting persons, which often reflects stake aggregation across entities.

What to watch: any additional Form 4 activity after 11/10/2025 (filing date), details in Exhibit 99.1 regarding ownership structure, and whether subsequent filings show continued accumulation or changes in indirect accounts. These items help clarify concentration of control and future governance dynamics over the coming quarters.

Insider Trade Summary

Net Buyer: 1,481,481 shares

Net Buy 2 txns

Insider SUVRETTA CAPITAL MANAGEMENT, LLC, Averill Madison Master Fund, Ltd., Averill Master Fund, Ltd., Cowen Aaron

Role Director, 10% Owner | Director, 10% Owner | Director, 10% Owner | 10% Owner

Bought 1,481,481 shs ($20.00M)

Type	Security	Shares	Price	Value
Purchase	Common stock, par value $0.0001 per share	730,370	$13.50	$9.86M
Purchase	Common stock, par value $0.0001 per share	751,111	$13.50	$10.14M

Holdings After Transaction: Common stock, par value $0.0001 per share — 1,819,812 shares (Indirect, See footnotes)

Footnotes (3)

1. F1. Notes are included on Exhibit 99.1.
2. F2. Notes are included on Exhibit 99.1.
3. F3. Notes are included on Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SUVRETTA CAPITAL MANAGEMENT, LLC

(Last) (First) (Middle)

540 MADISON AVENUE

7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Benitec Biopharma Inc. [ BNTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock, par value $0.0001 per share	11/07/2025		P		730,370(2)	A	$13.5(2)	9,538,175	I(1)	See footnotes(1)(2)
Common stock, par value $0.0001 per share	11/07/2025		P		751,111(3)	A	$13.5(3)	1,819,812	I(1)	See footnotes(1)(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

SUVRETTA CAPITAL MANAGEMENT, LLC

(Last) (First) (Middle)

540 MADISON AVENUE

7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Averill Madison Master Fund, Ltd.

(Last) (First) (Middle)

C/O SUVRETTA CAPITAL MANAGEMENT, LLC

540 MADISON AVENUE, 7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Averill Master Fund, Ltd.

(Last) (First) (Middle)

C/O SUVRETTA CAPITAL MANAGEMENT, LLC

540 MADISON AVENUE, 7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Cowen Aaron

(Last) (First) (Middle)

C/O SUVRETTA CAPITAL MANAGEMENT, LLC

540 MADISON AVENUE, 7TH FLOOR

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Notes are included on Exhibit 99.1.

2. Notes are included on Exhibit 99.1.

3. Notes are included on Exhibit 99.1.

Remarks:

Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer Information Exhibit 99.3 - Joint Filers' Signature

	Suvretta Capital Management, LLC; By: /s/Andrew Nathanson, General Counsel & Chief Compliance Officer	11/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.